Abstract
This study investigated the oncologic impact of loss of SMAD4 expression in resected left-sided pancreatic cancer and its correlation with tumor metabolism. From 2005 to 2011, the medical records of patients who underwent radical distal pancreatectomy for resectable pancreatic cancer were retrospectively reviewed. Formalin-fixed, paraffin embedded tissue from 32 patients was investigated. Clinicopathological characteristics, immunostaining of SMAD4, and positron emission tomography-based parameters were analyzed in relation to oncologic outcomes. Thirteen patients were women and 19 were men, with a mean age of 63 ± 9.4 years. Mean resected tumor size was 3.3 ± 1.5 cm. Ten patients (31.3%) showed loss of SMAD4 expression. No significant clinicopathological differences were noted according to SMAD4 expression (P > 0.05); however, patients with loss of SMAD4 showed significantly poorer disease-free survival (mean 57.4 months vs mean 17.6 months, P = 0.006). As a cut-off value, a SUV max of 4.5 was found to be predictive of loss of SMAD4 with a sensitivity of 75% and a specificity of 84.6%. In logistic regression analysis, SUV max >4.5 was found to infer a 16-fold higher risk for loss of SMAD4 in resected left-sided pancreatic cancers (Exp[β] = 16.5, P = 0.012, 95% confidence interval: 1.832-148.606). Loss of SMAD4 is associated with poor oncologic outcomes. SUV max can predict loss of SMAD4 in resected left-sided pancreatic cancer. SUV max may be a clinical biomarker for detecting loss of SMAD4 expression and predicting early systemic metastasis.
| Original language | English |
|---|---|
| Article number | e3452 |
| Journal | Medicine (United States) |
| Volume | 95 |
| Issue number | 17 |
| DOIs | |
| Publication status | Published - 2016 Apr 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
}
Maximum Standard Uptake Value as a Clinical Biomarker for Detecting Loss of SMAD4 Expression and Early Systemic Tumor Recurrence in Resected Left-Sided Pancreatic Cancer. / Kang, Chang Moo; Hwang, Ho Kyoung; Park, Jiae; Kim, Changsoo; Cho, Seong Kyoung; Yun, Mijin; Lee, Woo Jung.
In: Medicine (United States), Vol. 95, No. 17, e3452, 01.04.2016.Research output: Contribution to journal › Article
TY - JOUR
T1 - Maximum Standard Uptake Value as a Clinical Biomarker for Detecting Loss of SMAD4 Expression and Early Systemic Tumor Recurrence in Resected Left-Sided Pancreatic Cancer
AU - Kang, Chang Moo
AU - Hwang, Ho Kyoung
AU - Park, Jiae
AU - Kim, Changsoo
AU - Cho, Seong Kyoung
AU - Yun, Mijin
AU - Lee, Woo Jung
PY - 2016/4/1
Y1 - 2016/4/1
N2 - This study investigated the oncologic impact of loss of SMAD4 expression in resected left-sided pancreatic cancer and its correlation with tumor metabolism. From 2005 to 2011, the medical records of patients who underwent radical distal pancreatectomy for resectable pancreatic cancer were retrospectively reviewed. Formalin-fixed, paraffin embedded tissue from 32 patients was investigated. Clinicopathological characteristics, immunostaining of SMAD4, and positron emission tomography-based parameters were analyzed in relation to oncologic outcomes. Thirteen patients were women and 19 were men, with a mean age of 63 ± 9.4 years. Mean resected tumor size was 3.3 ± 1.5 cm. Ten patients (31.3%) showed loss of SMAD4 expression. No significant clinicopathological differences were noted according to SMAD4 expression (P > 0.05); however, patients with loss of SMAD4 showed significantly poorer disease-free survival (mean 57.4 months vs mean 17.6 months, P = 0.006). As a cut-off value, a SUV max of 4.5 was found to be predictive of loss of SMAD4 with a sensitivity of 75% and a specificity of 84.6%. In logistic regression analysis, SUV max >4.5 was found to infer a 16-fold higher risk for loss of SMAD4 in resected left-sided pancreatic cancers (Exp[β] = 16.5, P = 0.012, 95% confidence interval: 1.832-148.606). Loss of SMAD4 is associated with poor oncologic outcomes. SUV max can predict loss of SMAD4 in resected left-sided pancreatic cancer. SUV max may be a clinical biomarker for detecting loss of SMAD4 expression and predicting early systemic metastasis.
AB - This study investigated the oncologic impact of loss of SMAD4 expression in resected left-sided pancreatic cancer and its correlation with tumor metabolism. From 2005 to 2011, the medical records of patients who underwent radical distal pancreatectomy for resectable pancreatic cancer were retrospectively reviewed. Formalin-fixed, paraffin embedded tissue from 32 patients was investigated. Clinicopathological characteristics, immunostaining of SMAD4, and positron emission tomography-based parameters were analyzed in relation to oncologic outcomes. Thirteen patients were women and 19 were men, with a mean age of 63 ± 9.4 years. Mean resected tumor size was 3.3 ± 1.5 cm. Ten patients (31.3%) showed loss of SMAD4 expression. No significant clinicopathological differences were noted according to SMAD4 expression (P > 0.05); however, patients with loss of SMAD4 showed significantly poorer disease-free survival (mean 57.4 months vs mean 17.6 months, P = 0.006). As a cut-off value, a SUV max of 4.5 was found to be predictive of loss of SMAD4 with a sensitivity of 75% and a specificity of 84.6%. In logistic regression analysis, SUV max >4.5 was found to infer a 16-fold higher risk for loss of SMAD4 in resected left-sided pancreatic cancers (Exp[β] = 16.5, P = 0.012, 95% confidence interval: 1.832-148.606). Loss of SMAD4 is associated with poor oncologic outcomes. SUV max can predict loss of SMAD4 in resected left-sided pancreatic cancer. SUV max may be a clinical biomarker for detecting loss of SMAD4 expression and predicting early systemic metastasis.
UR - http://www.scopus.com/inward/record.url?scp=84978250967&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978250967&partnerID=8YFLogxK
U2 - 10.1097/MD.0000000000003452
DO - 10.1097/MD.0000000000003452
M3 - Article
C2 - 27124039
AN - SCOPUS:84978250967
VL - 95
JO - Medicine (United States)
JF - Medicine (United States)
SN - 0025-7974
IS - 17
M1 - e3452
ER -